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Introduction
Structural alterations or vascular remodelling, increased stiffness and endothelial dysfunction are key features of hypertension and are associated to vascular smooth muscle cells (VSMC) reorganization, increased extracellular matrix (ECM) deposition and altered contractility or impaired endothelium-dependent relaxation (Mulvany, 2008; Briones et al., 2010; Rizzoni and Agabiti-Rosei, 2012; Ponticos and Smith, 2014) . Both endothelial dysfunction and remodelling of small vessels are relevant prognostic factors of cardiovascular events in high-risk population (de Ciuceis et al., 2007; Mathiassen et al., 2007; Münzel et al., 2008) . Therefore, elucidating the mechanisms responsible for these alterations is of enormous interest.
It is recognized that chronic-low grade inflammation has a crucial role in the pathogenesis of hypertension (Savoia and Schiffrin, 2006) . The role of adaptive immunity in the pathogenesis of hypertension has been recently reported (for review, see de Ciuceis et al., 2014; Harrison, 2014; Schiffrin, 2014) . Angiotensin II (AngII) is now considered a proinflammatory mediator in hypertension through mechanisms involving reactive oxygen species (ROS) production that contribute to the observed vascular alterations. (Touyz, 2005; Briones et al., 2009; Briones and Touyz, 2010) . However, how the inflammation associated with this pathology is initiated has not been fully elucidated. Toll-like receptor 4 (TLR4) is a member of pattern recognition receptors which plays an important role mediating inflammatory response (Carpenter and O´Neill, 2009; McCarthy et al., 2014) . Besides being expressed in immune cells, TLR4 is ubiquitously expressed in cells of the cardiovascular system and in fact contribution of TLR4 signalling has been proposed in vascular inflammatory pathologies such as atherosclerosis, diabetes or metabolic syndrome (den Dekker et al., 2010; Jialal et al., 2014) . Moreover, we and others have recently described an emerging role for TLR4 in hypertension. Thus, TLR4 expression is increased in hypertension, and this expression seems to be associated with the increased blood pressure (Eiβler et al., 2011; Bomfin et al., 2012; Marketou et al., 2012; Sollinger et al., 2014; de Batista et al., 2014) . TLR4 is activated by lipopolysaccharide as well as by non-infectious hostendogenous compounds (damage-associated molecule patterns, DAMPs), such as heat shock proteins (HSP), fibrinogen and tenascin-C, many of which are present in hypertension as a consequence of chronic cell injury and death (Tsan and Gao, 2004; McCarthy et al., 2014) . Furthermore, AngII upregulates TLR4 expression that contributes to the proinflammatory effects of this factor (Wolf et al., 2006; Ji et al., 2009; Yuen et al., 2012) . In this sense, we have described that through AT1 receptors AngII contributes to the vascular TLR4 upregulation found in spontaneously hypertensive rats (SHR) (de Batista et al., 2014) . After activation, TLR4 signalling might occur via MyD88 (myeloid differentiation factor 88)-dependent or -independent pathways that ultimately activate NF-κB, which controls transcription of several proinflammatory genes (Carpenter and O´Neill, 2009; Kawai and Akira, 2010) .
Recent studies have demonstrated that TLR4 is involved in the vascular dysfunction observed in SHR and N G -nitro-L-arginine methyl ester (L-NAME)-induced hypertension (Sollinger et al., 2014; de Batista et al., 2014) . While the imbalance between Th1 effector and the anti-inflammatory Treg lymphocytes in the progression of vascular remodelling in hypertension has been proposed (Schiffrin, 2014; de Ciuceis et al., 2014; Harrison, 2014) , to the best of our knowledge, the involvement of TLR4 in the structural and mechanical alterations observed in this pathology has not still been explored. Therefore, we investigated whether TLR4 contributes to AngII-induced hypertension and the associated vascular structural, mechanical and functional alterations focusing on the role of oxidative stress in these alterations. Our findings F o r P e e r R e v i e w provide novel evidence that TLR4 mediates AngII-induced hypertension and inflammation as well as the vascular functional alterations and remodelling associated to this pathology. Our results also suggest that the JNK/NF-κB signalling pathways and increased oxidative stress from NAD(P)H oxidase and mitochondria may be implicated in these vascular effects through MyD88-dependent activation. The following C57BL6 male mice were used: 1) control mice treated with a nonspecific IgG (IgG 2a , 1 µg·day -1 , saline-diluted, i.p., Santa Cruz Biotechnology Inc., Dallas, TX, USA); 2) infused with AngII (1.44 mg·Kg -1 ·day -1 for 2 weeks, s.c. by Alzet osmotic minipumps, Alza Corp., Cupertino, CA, USA) and treated with IgG; 3) infused with AngII and treated with the neutralizing anti-TLR4 antibody (rat monoclonal IgG 2a , 1 µg·day -1 saline-diluted, i.p., Santa Cruz Biotechnology Inc.). For some experiments, control mice treated with anti-TLR4 antibody were also used; treatment did modify neither blood pressure nor structural and mechanical parameters of mesenteric arteries nor aortic vascular responses (results not shown). Treatments started 24 h prior to AngII infusion. Systolic BP was measured by tail-cuff plethysmography. In addition, VSMC obtained from adults SHR were also used.
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Tissue preparations
Animals were euthanized by CO 2 and aorta and first order branches of the mesenteric artery were dissected free of fat and connective tissue and maintained in cold (4°C) Krebs-Henseleit solution (KHS, in mM: 115 NaCl, 25 NaHCO 3 , 4.7 KCl, 1.2 MgSO 4 .7H 2 O, 2.5 CaCl 2 , 1.2 KH 2 PO 4 , 11.1 glucose, and 0.01 Na 2 EDTA) bubbled with a 95% O 2 -5% CO 2 mixture (pH=7.4). The analyses of vascular structure and function as well as NO production were made on the same day. For superoxide anion (O 2 .-) production measurement, segments were placed in KHS containing 30% sucrose for 20 min, transferred to a cryomold containing Tissue Tek OCT embedding medium and frozen in liquid nitrogen. For immunofluorescence and histological studies, arterial segments were fixed with 4% paraformaldehyde (PFA; in 0.2 M phosphate buffer, pH=7.2-7.4) for 1 h and washed in three changes of PBS. After washing, arterial segments were frozen as described above. Segments used for gene expression studies were immediately frozen in liquid nitrogen. Tissues were kept at -70°C until the day of the experiments. The hearts were removed to assess cardiac hypertrophy. For this, the ratio between the left ventricular wet weight and the length of the tibia was calculated.
Cell culture
Primary cultures of VSMC were obtained from thoracic aortas from 5 months-old SHR using the explant method (Martín et al., 2012) . Cells were identified as VSMC by morphological and growth characteristics and by positive immunocytochemical staining with a specific monoclonal anti-α-actin antibody (Sigma Chemical Co., St Louis, MO, USA). For experiments, cells from passages 2 to 5 were rendered quiescent by incubation in DMEM containing 0.2% FBS for 24 h. Cells were stimulated with 100 nM AngII (for the times indicated in the results section), with or without pretreatment for 1 h with the MyD88 inhibitor ST-2825 (20 µM) or the TLR4 inhibitor CLI-095 (1 µM).
Pressure myography
The structural and mechanical properties of small mesenteric arteries were studied with a pressure myograph (Danish Myo Tech, Model P100, J.P. Trading I/S, Aarhus, Denmark), as described (Briones et al., 2009) . Briefly, vessels were placed in calcium- ; omitting calcium and adding 1 mM EGTA) and a pressure-diameter curve was obtained by increasing intraluminal pressure in 20 mmHg steps from 3 to 120 mmHg. Internal and external diameters were continuously measured under passive conditions (D i0Ca , D e0Ca ) for 3 min at each intraluminal pressure. Finally, arteries were set to 45 mmHg in 0Ca 2+ -KHS and then pressure-fixed with 4% phosphate buffered PFA at 37°C for 60 min and kept at 4°C for confocal microscopy studies.
From internal and external diameter measurements in passive conditions the following structural and mechanical parameters were calculated:
Wall thickness (WT) = (D e0Ca − D i0Ca )/2 Wall:lumen = (D e0Ca − D i0Ca )/2D i0Ca Incremental distensibility represents the percentage of change in the arterial internal diameter for each mmHg change in intraluminal pressure, and was calculated according to the formula:
Incremental distensibility = ∆D i0Ca /(D i0Ca × ∆P) × 100 Circumferential wall strain (ε) = (D i0Ca -D 00Ca )/D 00Ca , where D 00Ca is the internal diameter at 3 mmHg and D i0Ca is the observed internal diameter for a given intravascular pressure, both measured in 0Ca 2+ medium. Circumferential wall stress (σ) = (P × D i0Ca )/(2WT), where P is the intraluminal pressure (1 mmHg = 1.334 × 10 3 dynes·cm -2 ) and WT is the wall thickness at each intraluminal pressure measured in 0Ca 2+ -KHS. Arterial stiffness independent of geometry is determined by the Young's elastic modulus (E =stress/strain). The stress-strain relationship is non-linear; therefore, it is more appropriate to obtain a tangential or incremental elastic modulus (E inc ) by determining the slope of the stress-strain curve (E inc =δσ/δε). E inc was obtained by fitting the stress-strain data from each animal to an exponential curve using the equation: σ =σ orig e βε , where σ orig is the stress at the original diameter (diameter at 3 mmHg). Taking derivatives on the equation presented earlier, we see that E inc = βσ. An increase in β implies an increase in E inc , which means an increase in stiffness.
Confocal microscopy study of nuclei distribution
Quantification of nuclei distribution was analyzed in pressure-fixed intact mesenteric segments, as described (Arribas et al., 1997) . Briefly, arteries were incubated with the nuclear dye Hoechst 33342 (Sigma Chemical Co.) (0.01 mg·ml -1 ) and visualized with a Leica TCS SP2 confocal system (Leica Microsystems, Wetzlar, Germany, ×40 objective, zoom ×3.5). Metamorph image analysis software (Universal Imaging, Molecular Devices Corp., Downingtown, PA, USA) was used for quantification.
To allow comparisons the following calculations were performed on the basis of 1-mm-long segments: artery volume (mm 3 ) [volume = wall CSA (mm 2 ) × 1 mm]; total number of adventitial and smooth muscle cells (cell n = n of nuclei per stack × n of stacks per artery volume); total number of endothelial cells [calculated per luminal surface of 1-mm-long artery; luminal surface area = 2π x diameter (mm) × 1 mm /2].
Organization of internal elastic lamina
The elastin organization within the internal elastic lamina (IEL) was studied in segments of small mesenteric arteries, using fluorescence confocal microscopy based on the autofluorescent properties of elastin (Ex 488 nm and Em 500-560 nm), as previously described (Briones et al., 2003) . Briefly, intact pressure-fixed segments were visualized with a Leica TCS SP2 confocal system. From each stack of serial images, individual projections of the IEL were reconstructed, and total fenestrae number and fenestrae area were measured using Metamorph Image Analysis Software. 
Collagen determination
Mesenteric arteries were cut into 5 µm sections using a cryostat. Collagen was quantified in Picro-sirius red-stained sections [0.1% (wt·vol -1 ) Sirius red 3FB in saturated aqueous picric acid for 30 min with gentle agitation]. Three-four sections from each animal were analyzed under microscopy transmitted light (Leica DM 2000, Leica Microsystems) using an Image System Analysis (Leica LAS Image Analysis, Leica Microsystems). The area of collagen in the media layer was identified after excluding perivascular fibrosis of the vessel as the ratio of collagen deposition to the total media area.
Histological analysis
Cross sections (14 µm) from aortas were stained with hematoxylin-eosin. All images were acquired at room temperature using a microscope (Leica DM 2000) . Morphometric determinations of the lumen and vessel areas were performed by using Metamorph Image Analysis Software. All microscopic images of the sections were traced for the calculations of the areas. To determine the luminal area, the crosssectional area enclosed by the IEL was corrected to a circle by applying the form factor l 2 /4π to the measurement of the IEL, where l is the length of the lamina. Vessel area was determined by the cross-sectional area enclosed by the external elastic lamina corrected to a circle, applying the same form factor (l 2 /4π) to the measurement of the external elastic lamina. The media area was calculated as the difference between the corrected vessel and luminal areas. Internal and external diameters were calculated from luminal and vessel areas, respectively. This method avoids miscalculations of areas caused by eventual collapse of the immersion-fixed arteries.
Vascular function
Reactivity of mice aorta was studied in a wire myograph. After a 30-min equilibration period in oxygenated KHS, arterial segments were stretched to their optimal lumen diameter for active tension development. Segments contractility was then tested by an initial exposure to a high-K + solution (K + -KHS, 120 mM). The presence of endothelium was determined by the ability of 10 µM ACh to relax arteries precontracted with phenylephrine at approximately 50% the K + -KHS contraction. Afterwards, a single concentration-response curve to ACh (1 nM-10 µM), phenylephrine (1 nM-10 µM) and diethylamine NONOate (DEA-NO, 3 nM-10 µM) was performed. The effects of the hydrogen peroxide detoxificant catalase (1000 U·ml -1 ), the NAD(P)H oxidase inhibitor apocynin (0.3 mM), the selective NOX-1 inhibitor ML-171 (2-acetylphenothiazine, 0.5 µM), the mitochondrion-targeted SOD2 mimetic Mito-TEMPO (0.5 µM) or the nonselective inhibitor of NO synthesis, L-NAME (100 µM) on phenylephrine-or AChinduced responses were analyzed. These drugs were incubated 30 min prior to phenylephrine.
Immunofluorescence TLR4 in aorta was immunolocalized as described (de Batista et al., 2014) . Briefly, frozen transverse sections (14 µm) were incubated with a polyclonal antibody against TLR4 (1:100, Santa Cruz Biotechnology Inc.) in PBS containing 2% bovine serum albumin for 1 h at 37ºC in a humidified chamber. After washing, rings were incubated with the secondary antibody goat anti-rat (1:200) IgG labelled with alexa fluor-546 dye (Molecular Probes Inc., Eugene, OR, USA), for 1 h at 37ºC in a humid box. Nuclei were stained with 0.01 mg·ml -1 Hoechst 33342. Immunofluorescent signals were viewed using an inverted Leica TCS SP2 confocal laser-scanning microscope with oil immersion lens. The specificity of the immunostaining was evaluated by omission of F o r P e e r R e v i e w the primary antibody and processed as above. Under these conditions, no staining was observed in the vessel wall.
Immunofluorescence was also used to detect p65 NF-κB subunit nuclear protein expression in cultured VSMC stimulated with AngII (100 nM, 45 min) after treatment or not with CLI-095 (1 µM, 1h), as described (Pérez-Girón et al., 2014) . Cells were incubated overnight at 4°C with a rabbit polyclonal primary antibody against p65 (1:250, Santa Cruz Biotechnology). After washing, cells were incubated with a FITCconjugated goat anti-rabbit secondary antibody (1:200, Molecular Probes, Life Technologies Ltd, Paisley, UK). Then, cells were counterstained for 15 min with DAPI (1:10,000, Invitrogen Life Technologies) and visualized under a fluorescence microscope (Zeiss, Axioplan 2, Carl Zeiss Microscopy, LLC, Thornwood, NY, USA). At least three independent experiments were performed.
Quantitative PCR real time (qRT-PCR) assay mRNA levels were determined in mice aortic homogenates. Total RNA was obtained using TRI Reagent (Sigma Chemical Co.) according to the manufacturer's recommendations. A total of 1 µg of DNAse I treated RNA was reverse-transcribed using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) in a final volume of 10 µl. qPCR was performed using the fluorescent dye SyBRGreen (iTaq FAST SyBRGreen Supermix with ROX, Bio-Rad, USA). β2-microglobulin (Rn00560865_m1, Applied Biosystems) or 36B4 were used as internal controls. All qPCRs were performed in duplicate. Primer sequences are: for TLR4, FW: TGTGCCTTCAAAACATGACTGG, RV: CTCCCAAGATCAACCGATGG; p22phox, FW: ATCTGTCTGCTGGAGTAT, RV: CGTAGTAATTCCTGGTGAG; NOX-1, FW: CAGCGTGCCGACAACAAG; RV: CCAGCCAGTGAGGAAGAGAC; TNF-α, FW: CCACGCTCTTCTGTCTACTG, RV: TGAGGGTCTGGGCCATAGA; MCP-1 (monocyte chemoattractant protein-1), FW: CATCCACGTGTTGGCTCA, RV: GATCATCTTGCTGGTGAATGAGT; IL-6, FW: TGATGGATGCTACCAAACTGG, RV:
TTCATGTACTCCAGGTAGCTATGG; 36B4, FW: AGATGCAGCAGATCCGCAT, RV: GTTCTTGCCCATCAGCACC. qRT-PCR was carried out in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems) using the following conditions: 2 min 50°C, 10 min 95°C and 40 cycles: 15 s 95ºC, 1 min 60ºC. At the end of the PCR, melting curve analysis was performed to show PCR product specificity. To calculate the relative index of gene expression, we employed the 2 −∆∆Ct method using untreated samples as calibrator.
Measurement of O 2 .-production The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate production of O 2 .-in situ, as previously described (Martínez-Revelles et al., 2013) . Briefly, aortic sections were incubated in buffer containing DHE (2 µM, 30 min, 37ºC) and then viewed by a fluorescent laser-scanning confocal microscope (Leica TCS SP2; Ex 561 and Em 610 nm), using the same imaging settings in each case. As a negative control, parallel sections were preincubated with tempol (100 µM). In these conditions, no staining was observed in the vascular wall. O 2 .-production was quantitatively analyzed with MetaMorph Image Analysis Software.
NAD(P)H oxidase activity
The lucigenin-enhanced chemiluminescence assay was used to determine the superoxide anion generated by NAD(P)H oxidase activity, as described (Pérez-Girón et al., 2014) . Tissues were homogenized in a lysis buffer (in mM: KH 2 PO 4 50, ethylene glycol tetraacetic acid 1, sucrose 150, pH=7.4). The reaction was started by the addition F o r P e e r R e v i e w of NAD(P)H (0.1 mM) to the suspension containing sample, lucigenin (5 µM), and assay phosphate buffer. The luminescence was measured in a plate luminometer (AutoLumat LB 953, Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany). Buffer blank was subtracted from each reading. Activity was expressed as relative light units·mg -1 protein. Samples from control+IgG-treated mice or untreated cells were used as controls, and variations of activity were calculated as the amount relative to controls.
Nitric oxide release NO production was determined in aortic segments with the fluorescent probe 4,5-diaminofluorescein (DAF-2), as described (Martínez-Revelles et al., 2013) . Briefly, aortic segments were incubated with DAF-2 (2 µM) for 45 min. Afterwards, basal and ACh-stimulated NO release were measured using a spectrofluorimeter (FLUOstar OPTIMA BMG Labtech). To avoid variations in fluorescence among the different days, all experimental conditions were measured each day. The amount of NO released was expressed as arbitrary units·mg -1 tissue.
Western blot analysis
Protein expression was determined in whole cell lysates (20 µg protein) or nuclear extracts (15 µg protein) by Western blot, as described. Proteins were separated by 15% SDS-PAGE and then transferred to polyvinyl difluoride membranes overnight. Membranes were incubated with rabbit polyclonal antibody for p-JNK1/2 (1:1,000, Cell Signaling Technology Inc, Danvers, MA, USA) or p65 (1:1,000). Immunoreactive bands were visualized using fluorescent secondary antibodies from rabbit (1:5,000, BioRad, Laboratories, Hercules, CA, USA) and ECF Plus Western blot analysis system (GE Healthcare; Little Chalfont, UK). Signals on the immunoblot were quantified using the Typhoon 9210 quantification software (GE Healthcare). The same membrane was used to determine JNK (monoclonal antibody anti-JNK, 1:1,000, Cell Signaling Technology Inc) in cellular lysates and Histone-3 (rabbit polyclonal antibody antiHistone-3, 1:500, Santa Cruz Biotechnology) in nuclear extracts. Results are expressed as the ratio between signals on the immunoblot corresponding to the different proteins and total JNK or Histone-3 in the same preparation. To compare results for protein expression within the same experiment and with others, we assigned a value of 1 in each gel to the expression of unstimulated control cells and used that value to calculate the relative density of other bands from the same gel.
Statistical analysis and drugs
Vasoconstrictor responses were expressed as a percentage of the tone generated by K + -KHS. Vasodilator responses were expressed as the percentage of the previous tone induced by phenylephrine in each case. The maximum response (Emax) and pD 2 values were calculated by non-linear regression analysis of each individual concentration-response curve using GraphPad Prism Software (San Diego, CA, USA). To compare the effect of L-NAME on the response to phenylephrine in segments from the three groups, results were expressed as the differences of areas under the concentration-response curves (dAUC) in the control and experimental situations. AUCs were calculated from the individual concentration-response curve plots using GraphPad Prism Software; differences were expressed as the percentage of the AUC of the corresponding control situation.
All values are expressed as mean ± SEM of the number of animals or different cultures (each obtained from three different animals) used. Results were analyzed by using unpaired Student's t-test or two-way ANOVA followed by Bonferroni's post hoc F o r P e e r R e v i e w test or Mann-Whitney nonparametric test by using GraphPad Prism Software. A P < 0.05 was considered significant. l-phenylephrine hydrochloride, ACh chloride, catalase, apocynin, L-NAME, and ML-171 were purchased from Sigma Chemical Co, mito-TEMPO from Santa Cruz Biotechnology Inc., DHE from Invitrogen, CLI-095 from Invivogen (San Diego, CA, USA) and ST-2825 from MedChem Express (Princeton, NJ, USA). All drugs were dissolved in distilled water, except for CLI-095 and ST-2825, which were dissolved in dimethyl sulfoxide (DMSO); 10 µl of DMSO did not have any effect on VSMC.
The receptor nomenclature conforms to BJP´s Concise Guide to Pharmacology according to Alexander et al. (2013) . 
Results
TLR4 mediates AngII-induced hypertension and inflammation
TLR4 mRNA levels were greater in aortic segments from AngII-infused mice when compared with controls ( Figure 1A) ; TLR4 expression was increased in all layers of the vascular wall ( Figure 1A) .
Treatment with anti-TLR4 partially prevented the increased SBP observed in AngII-infused mice ( Figure 1B) , although neither body weight (data not shown) nor left ventricular hypertrophy were affected ( Figure 1C) .
Aortic segments from AngII-infused mice showed increased mRNA levels of TNFα, IL-6 and MCP-1 that were prevented by anti-TLR4 treatment ( Figure 1D ).
TLR4 mediates vascular remodelling and mechanical alterations
In small mesenteric arteries from AngII-infused mice, vessel and lumen diameters were reduced, while wall thickness and wall:lumen ratio were increased when compared with controls (Figure 2A-D) . Treatment of AngII-infused mice with anti-TLR4 antibody improved these structural parameters ( Figure 2A-D) ; the treatment also improved the reduced number of smooth muscle and endothelial cells observed in mesenteric arteries from AngII-infused mice ( Figure 2E ).
AngII infusion reduced incremental distensibility ( Figure 3A ) and increased vessel stiffness of mesenteric arteries, as shown by the leftward shift of the stress-strain relationship and the larger β value ( Figure 3B ) that were prevented by anti-TLR4 antibody treatment ( Figure 3A,B) . AngII reduced the number and size of fenestrae in the IEL ( Figure 3C ) and increased the collagen deposition ( Figure 3D ). Anti-TLR4 treatment improved fenestrae size and decreased collagen deposition ( Figure 3C,D) .
In aorta from AngII-infused mice, the media thickness, media:lumen ratio and cross-sectional area were increased when compared with controls; treatment with anti-TLR4 antibody prevented these structural alterations (Figure 4 ).
TLR4 mediates alterations on vascular function
Phenylephrine-induced contractile responses were greater in aortic segments from AngII-infused than control mice and these responses were reduced by anti-TLR4 antibody treatment ( Figure 5A ). Treatment also improved the reduced ACh-induced endothelium-dependent vasodilatation observed in aorta from AngII-infused mice ( Figure 5B ). Endothelium-independent relaxation induced by DEA-NO was similar in the three groups ( Figure 5C ).
TLR4 mediates vascular ROS production
The increased AngII-induced ROS production may contribute to the vascular alterations occurring in hypertension (Briones and Touyz, 2010; Virdis et al., 2011) . As expected, O 2 .-production was greater in the aortic wall from AngII-infused than control mice; this was particularly evident in adventitia and media layers ( Figure 6A ). Aortic NAD(P)H oxidase activity ( Figure 6B ) and p22phox and NOX-1 mRNA levels ( Figure  6C ) were also greater in AngII-infused than control mice. Anti-TLR4 antibody treatment prevented the increased O 2 .-production, NAD(P)H oxidase activity and NOX-1 mRNA levels, without modifying p22phox levels ( Figure 6 ).
We have previously described that AngII increases oxidative stress in VSMC through TLR4 activation (de Batista et al, 2014) . Herein we observed that AngII (1 h)-induced NAD(P)H oxidase activity was reduced by the MyD88 inhibitor ST-2825 ( Figure 7A ). We have also reported that AngII increases oxidative stress in VSMC through JNK1/2 MAPK and NF-κB (Pérez-Girón et al., 2014) . The AngII (10 min)-F o r P e e r R e v i e w induced JNK1/2 phosphorylation was reduced by the TLR4 inhibitor CLI-095 ( Figure  7B ). In addition, the increased nuclear expression and cytosol to the nucleus translocation of the p65 NF-κB subunit induced by AngII (45 min) was also reduced by CLI-095 ( Figure 7C,D) .
TLR4 mediates the contribution of oxidative stress to altered vascular function
We then assessed whether the increased ROS production associated with TLR4 upregulation contributes to the hypertension-associated vascular dysfunction. Catalase, apocynin, ML-171 and Mito-TEMPO did not affect phenylephrine-induced contraction in control mice, but they reduced those responses in AngII-infused mice; treatment of AngII-infused mice with the anti-TLR4 antibody abolished the inhibitory effect of the four antioxidants (Figure 8) . Similarly, catalase, apocynin, ML-171 and Mito-TEMPO increased ACh-induced relaxation only in AngII-infused mice; anti-TLR4 antibody treatment abolished these effects (Figure 9 ). Altogether, these results suggest that TLR4 increased oxidative stress that would contribute to the impaired vascular function observed in hypertensive mice.
TLR4 reduces NO release and its participation in phenylephrine contraction
Thereafter, we evaluated the effects of the anti-TLR4 antibody treatment on the vascular NO release and its contribution to vasoconstrictor responses. In aorta from AngII-infused mice we observed a reduced NO release that was normalized by anti-TLR4 treatment ( Figure 10A) . Furthermore, the NOS inhibitor L-NAME leftward shifted the concentration-response curve to phenylephrine more in segments from control than AngII-infused mice; the anti-TLR4 antibody treatment restored this effect ( Figure 10B and Table 1 ), indicating that the decreased NO involvement to phenylephrine contraction after AngII infusion is restored by TLR4 blockade. 
Discussion
The results of the present study demonstrate, for the first time, that upregulation of TLR4 by AngII participates in the pathogenesis of hypertension by affecting, not only the function, but also the structure and the mechanical properties of the vasculature by mechanisms likely involving oxidative stress. MyD88-dependent mechanisms and the JNK/NF-κB signalling pathways might contribute to these effects.
Hypertension has been described as an inflammatory disease in which the inadequate activation of immune system may contribute to its pathophysiology (Savoia and Schiffrin, 2006; de Ciuceis et al., 2014; Harrison, 2014; McCarthy et al., 2014; Schiffrin, 2014; Virdis et al., 2014) . The role of adaptive immunity as contributor of hypertension has been widely reported. Thus, subsets of T lymphocytes have been involved in the development of hypertension and vascular remodelling in different hypertension models (de Ciuceis et al., 2014; Harrison, 2014; Schiffrin, 2014; Virdis et al., 2014) . Moreover, in the last years, activation of TLR4 has become a new research focus because of evidence that TLR4 is upregulated in hypertension contributing to its occurrence (Eiβler et al., 2011; Bomfin et al., 2012; de Batista et al., 2014; Sollinger et al., 2014) . The increased expression of TLR4 by AngII is one of the proposed mechanisms explaining the involvement of this receptor in hypertension. Thus, AngII induces inflammatory responses via TLR4 activation. In this sense, in VSMC AngII, through AT1 receptors, activates TLR4 leading to ERK1/2 and NF-κB activation and hence inflammatory response (Ji et al., 2009) ; moreover, osteocalcin-induced AngII release activates PKCδ/TLR4/ROS/cyclooxygenase-2 signalling cascade that contributes to vascular fibroblasts transformation to myofibroblasts (Yuen et al., 2012) . Recently we have shown that treatment with an AT1 receptor blocker reduced the increased TLR4 levels in SHR (de Batista et al., 2014) . Herein we observed that AngII infusion increased aortic TLR4 expression. More importantly, anti-TLR4 antibody treatment prevented the increased blood pressure and vascular proinflammatory cytokine levels, confirming the role of TLR4 to the AngII-induced hypertension and the associated inflammation. In agreement, in SHR this treatment reduced blood pressure (Bomfim et al., 2012; de Batista et al., 2014) and the increased vascular proinflammatory cytokine levels (Bomfim et al., 2015) . Further experiments are necessary to ascertain the exact mechanisms by which AngII upregulates TLR4 signalling pathway in our hypertension model.
The role of TLR4 in hypertension might rely on its effects on vascular structure and mechanical properties. TLR4 is involved in the outward arterial remodelling after atherosclerotic plaque formation (Hollestelle et al., 2004) and TLR through MyD88-dependent mechanisms contributes to the flow-mediated inward remodelling of conduit arteries (Tang et al., 2008) . Furthermore, TLR4 gene Asp299Gly polymorphism is associated with increased carotid artery compliance in young adults (Hernesniemi et al., 2008) . Our study provides evidence that TLR4 blockade prevents AngII-induced vascular remodelling and mechanical alterations, which might further contribute to the anti-hypertensive effects of the anti-TLR4 antibody treatment. Of note, these effects on vessel structure are observed in both conductance and resistance arteries, as demonstrated by the decreased wall:lumen ratio and wall thickness, which are wellknown predictors of cardiovascular risk (Rizzoni and Agabiti-Rosei, 2012) . Normalization of vessel structure by anti-TLR4 antibody treatment was achieved by improvement of cell number, which is reduced after AngII (Briones et al., 2009) . Moreover, TLR4 blockade prevented the AngII-induced increased collagen deposition and altered elastin structure, probably accounting for the restored wall:lumen ratio and the diminished vessel stiffness observed in response to anti-TLR4 treatment. Accordingly, in human VSMC the endogenous ligand for TLR4 HSP70 increases fibronectin and collagen type-I (González- Ramos et al., 2013) . Besides improving vascular structure and mechanics, anti-TLR4 treatment normalized contractile responses and endothelial function in aortic segments from AngII-infused mice, in agreement with studies in SHR (Bomfin et al., 2012; de Batista et al., 2014) . Moreover, we herein demonstrate that anti-TLR4 treatment also prevented the decreased endothelial cells number induced by AngII, thus providing a novel mechanism for endothelial improvement after TLR4 blockade.
One of the mechanism by which TLR4 blockade might prevent hypertension development and improve the vascular alterations found in AngII-infused mice is by reducing oxidative stress. Earlier studies described that antioxidants prevented hypertension development and structural alterations of both resistance and conductance arteries in AngII-infused mice (Virdis et al., 2004; Martínez-Revelles et al., 2013) . The mechanisms responsible for the vascular alterations induced by increased ROS production include VSMC proliferation and migration, oxidation of matrix metalloproteinases and generation of matrix proteins such as collagen (Virdis et al., 2004; Briones et al., 2009; Drummond et al., 2011) . Furthermore, the increase of ROS has been extensively reported to be responsible for endothelial dysfunction in hypertension (Briones and Touyz, 2010; Virdis et al., 2011) . In addition, increased ROS production by TLR4 pathway contributes to the AngII effects on mesangial cells apoptosis and fibroblasts differentiation (Lv et al., 2009; Yuen et al., 2012) . Herein, we found that anti-TLR4 antibody treatment reduced the increased NOX-1 expression, NAD(P)H oxidase activity and superoxide anion production observed in aorta from AngII-infused mice. Additionally, this treatment also abolished the effect of different antioxidants on both vasoconstrictor and vasodilator responses, confirming that TLR4 contributes to the endothelial dysfunction in AngII-induced hypertension by increasing oxidative stress, as suggested recently in other hypertension models (de Batista et al., 2014; Sollinger et al., 2014) . Our results point to both NAD(P)H oxidase and mitochondria as sources for the TLR4-induced oxidative stress. As a result of oxidative stress reduction by anti-TLR4 antibody treatment, NO bioavailability might be increased. Thus, TLR4 blockade increases NO release and its contribution to the phenylephrine-induced vasoconstriction in AngII-infused mice. Accordingly, in obese and diabetic mice, TLR4 activation increases ROS levels leading to a reduced NOproduction and bioavailability (Liang et al., 2013) . The increased NO would also be related to the above mentioned increased number of endothelial cells. Altogether, our results suggest that oxidative stress reduction by TLR4 blockade might account for the beneficial effects not only on the functional but also on the structural and mechanical vascular alterations. Although the role of oxidative stress after TLR4 activation on vascular remodelling in hypertension has not been previously explored, superoxideinitiated inflammation is necessary for MyD88-dependent inward remodelling of conduit arteries induced by flow (Tang et al., 2008) . Interestingly, TLR4 activation contributes to the vascular dysfunction associated with hypertension in SHR by cyclooxygenase-dependent mechanisms (Bomfim et al., 2012) . Contractile prostanoids from COX-2 contribute to hypertension and also to the functional alterations observed in AngII-infused mice and this is in part dependent on ROS (Martínez-Revelles et al., 2013) . Therefore, it is possible that by affecting oxidative stress status, TLR4 also modulates the COX pathway and its contribution to the vascular alterations associated with our hypertension model. TLR4 signals through different adaptor proteins, mainly MyD88, ultimately activating NF-κB which promotes transcription of different proinflammatory genes F o r P e e r R e v i e w (Kawai and Akira, 2010) . Another signalling pathway recruited by TLR4 activation via MyD88-dependent pathway is the MAPK cascade (Kawai and Akira, 2010) . Previously we have shown that JNK and NF-κB contributes to the AngII-induced oxidative stress (Pérez-Girón et al., 2014) . Herein we found, in VSMC, that AngII-induced NAD(P)H oxidase activity was reduced by a specific MyD88 inhibitor. Additionally, the TLR4 antagonist CLI-095 reduced the AngII-induced increased p65 nuclear expression and JNK1/2 phosphorylation. Altogether, our results suggest that after TLR4 upregulation, through the MyD88-dependent signalling pathway, AngII activates NF-κB/JNK, which would contribute to the increased oxidative stress and inflammation occurring in hypertension. Accordingly, Bonfim et al. (2015) have recently shown in SHR mesenteric arteries that TLR4 signalling is activated, leading to activation of MyD88/NF-κB pathway.
In conclusion, TLR4 upregulation by AngII contributes to the inflammation, endothelial dysfunction, vascular remodelling, extracellular matrix alterations and vascular stiffness associated with hypertension. These effects might be mediated by the MyD88/NF-κB/JNK pathways and increased oxidative stress from NAD(P)H oxidase and mitochondria. Although the role of adaptive immunity and T lymphocytes on vascular remodelling has been established (de Ciuceis et al., 2014; Harrison, 2014; Schiffrin, 2014; Virdis et al., 2014) , to the best of our knowledge, this is the first time that the TLR4 signalling pathway is described to contribute to the vascular structural and mechanical alterations observed in hypertension. The fact that TLR is expressed not only in the immune but also in vascular cells allows to suggest that TLR4 might be the link between low-grade inflammation, vascular remodelling and hypertension. The current model is that in hypertension, the elevated circulating levels of several compounds which act as DAMPs, such as AngII, after being recognized by TLRs on antigen-presenting cells, would originate the activation of T cells; the release of cytokines and chemokines causes inflammation and subsequently vascular damage through several mechanisms, including oxidative stress. This results in increased blood pressure, leading to further damage which would increase the release of DAMPs, creating a positive feed-back loop which contributes to the maintenance of hypertension (de Ciuceis et al., 2014; Harrison, 2014; Schiffrin, 2014) . Therefore, our observations open new antihypertensive therapeutic perspectives using agents that interfere with the TLR4 signalling pathway. Figure 9 . TLR4 inhibition reduces the involvement of oxidative stress on vasodilator responses in aorta from AngII-infused mice. Effect of catalase (1000 U·ml -1 ), apocynin (0.3 mM), ML-171 (0.5 µM) and Mito-TEMPO (0.5 µM) on the concentration-response curve to ACh in aortic segments from mice treated with a nonspecific IgG, with AngII plus a non-specific IgG or with AngII plus anti-TLR4 antibody. * P < 0.05. n=5-11. G -nitro-L-arginine methyl ester (L-NAME, 100 µM) on the concentration-response curve to phenylephrine (Phe) in aortic segments from the three groups of mice. Differences of the area under the concentration-response curve (dAUC) to Phe in the presence and the absence of L-NAME are also shown. *P < 0.05 vs Control or vs Control + IgG, # P < 0.05 vs AngII + IgG. n=5-9. The enhancing effect of L-NAME in Emax is expressed as fold increase over control situation.*P < 0.05 vs Control; # P < 0.05 vs Control + IgG mice; $ P <0.05 vs Ang + IgG mice; n=5-9.
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